文献速递生殖医学产科

国际辅助生殖技术监测委员会2014年全球报告:辅助生殖技术利用率、有效性与安全性

International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014†.
PubMed 文献 · Hum Reprod · 2021-01-01

五年趋势显示成功率与冻胚移植比例上升、累计活产率提高、单胚胎移植持续增加使多胎率下降,而卵胞浆内单精子注射使用趋于稳定。

要点

  • 新鲜非供卵周期单胚胎移植率从2010年30.0%升至2014年40.0%,双胎率从20.4%降至16.2%。
  • 每取卵累计活产率从2010年27.1%升至2014年32.1%,冻胚移植单胚胎移植率61.6%。

核心结论

  • 全球辅助生殖治疗的有效性与安全性持续提高,但治疗可及性、操作方式和胚胎移植实践存在显著差异。

主要发现

  • 2010至2014年,报告的非供卵取卵周期和冻胚移植周期分别增加37.3%和67.5%。
  • 非供卵辅助生殖中女性年龄≥40岁比例从2010年23.2%升至2014年27.0%。
  • 卵胞浆内单精子注射占非供卵取卵周期比例稳定在64.8%。
  • 新鲜取卵周期和冻胚移植周期的体外受精/卵胞浆内单精子注射联合分娩率分别为19.9%和24.3%。
  • 新鲜非供卵周期平均移植胚胎数从1.95降至1.73,三胎率从1.1%降至0.5%。

关键数值与推荐

  • 2014年冻胚移植非供卵周期单胚胎移植率61.6%,平均移植胚胎1.43个,双胎率10.1%,三胎率0.2%。
  • 每取卵累计分娩率从2010年27.1%升至2014年32.1%。

临床怎么用

  • 临床应关注单胚胎移植的持续推广以降低多胎率,并参考冻胚移植的较高分娩率优化策略。
  • 需注意不同国家间胚胎移植实践差异较大,应结合本地数据与指南个体化决策。

局限性

  • 数据依赖各国直接或通过区域登记处提交的质量与完整性,仅覆盖全球约三分之二的辅助生殖活动。
  • 中国作为全球周期主要贡献者未纳入本报告。
  • 本报告引入新的利用率和婴儿数估算方法,结果与既往报告不可直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What were the utilization, effectiveness and safety of practices in assisted reproductive technologies (ART) globally in 2014 and what global trends could be observed? SUMMARY ANSWER: The estimated total number of ART cycles conducted in 76 participating countries in 2014 was 1.93 million representing ∼66% of global activity, with 5-year trends including an increase in success rates and proportion of frozen embryo transfer (FET) cycles, improvement in cumulative live birth rates per aspiration, a continued increase in single embryo transfer (SET) and thus a reduction in multiple birth rates, an increase in preimplantation genetic testing and stabilization in the use of intracytoplasmic sperm injection (ICSI). WHAT IS KNOWN ALREADY: ART is widely practiced throughout the world but continues to be characterized by significant disparities in utilization, practice, effectiveness and safety. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) annual world report series provides an important instrument for tracking trends in ART treatment and for providing clinical and public health data to ART professionals, health authorities, patients and the general public. STUDY DESIGN, SIZE, DURATION: A retrospective, cross-sectional survey on ART procedures performed globally during 2014 was carried out. A new method for calculating ART utilization rates and number of babies born was introduced in this latest ICMART world report. PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 76 countries and 2 746 ART centres submitted data through national and regional ART registries on ART cycles performed during 2014 and their treatment and pregnancy outcomes. ART cycles and outcomes are described at a country level, regionally and globally. Aggregate country data are processed and analyzed based on methods developed by ICMART. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1 629 179 ART cycles were reported for the treatment year 2014. After imputing data for missing values and non-reporting centres in reporting countries, an estimated 1 929 905 cycles resulted in >439 039 babies in reporting countries. From 2010 to 2014, the number of reported non-donor aspirations and FET cycles increased by 37.3% and 67.5%, respectively. The proportion of women aged ≥40 years undergoing non-donor ART increased from 23.2% in 2010 to 27.0% in 2014. ICSI, as a percentage of non-donor aspiration cycles, remained relatively stable at 64.8%. The IVF/ICSI combined delivery rates per fresh aspiration and FET cycle were 19.9% and 24.3%, respectively. In fresh non-donor cycles, SET increased from 30.0% in 2010 to 40.0% in 2014, while the average number of transferred embryos decreased from 1.95 to 1.73-but with wide country variation. The rate of twin deliveries following fresh non-donor transfers continued to decrease, from 20.4% in 2010 to 16.2% in 2014, and the triplet rate decreased from 1.1% to 0.5%. In FET non-donor cycles in 2014, the SET rate was 61.6%, with an average of 1.43 embryos transferred, resulting in twin and triplet rates of 10.1% and 0.2%, respectively. The cumulative delivery rate per aspiration increased from 27.1% in 2010 to 32.1% in 2014. The overall perinatal mortality rate per 1 000 births was 19.4 following fresh IVF/ICSI cycles and 9.5 following FET cycles. Among reporting countries, oocyte donation cycles represented 7.3% of all embryo transfers (89 751 transfer cycles) and resulted in 39 278 babies. LIMITATIONS, REASONS FOR CAUTION: The data presented are dependent on the quality and completeness of data submitted by individual countries to ICMART directly or through regional registries. This report covers approximately two-thirds of world ART activity. China is a major contributor of global cycles missing from this report. Continued efforts to improve the quality and consistency of ART data reported by registries are still needed, including the use of internationally agreed standard definitions (The International Glossary of Infertility and Fertility Care). A new method was introduced in this report to calculate ART utilization and number of babies born following ART; therefore, these results are not directly comparable with previous reports. WIDER IMPLICATIONS OF THE FINDINGS: The ICMART world reports provide the most comprehensive global statistical census and review of ART utilization, effectiveness, safety and quality. While ART treatment effectiveness and safety continue to increase globally, the wide disparities in access to treatment, procedures performed and embryo transfer practices warrant attention by clinicians and policymakers. The new method for estimating ART utilization and number of babies born provided more conservative estimates compared to the previuos method. STUDY FUNDING/COMPETING INTEREST(S): ICMART receives unrestricted grants from Abbott and Ferring Pharmaceuticals. ICMART also acknowledges financial support from the following organizations: American Society for Reproductive Medicine; Asia Pacific Initiative on Reproduction; European Society of Human Reproduction and Embryology; Fertility Society of Australia and New Zealand; Japan Society for Reproductive Medicine; Japan Society of Fertilization and Implantation; Red Latinoamericana de Reproducción Asistida; and the Society for Assisted Reproductive Technology. S.D. reports industry sponsorship for attendance of conference from Ferring, and research grants to support African Network and Registry of ART from Ferring and Merck outside the submitted work. F.Z.-H. reports lectures at organized webinars for Ferring and Merck. O.I. reports honoraria for consulting from Ferring, Merck and ObsEva, as well as honoraria for lectures from Ferring and Merck. G.M.C., J.d.M., M.B., M.S.K. and G.D.A. have nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Chambers GM, Dyer S, Zegers-Hochschild F, et al. International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014†. Hum Reprod. 2021. PMID: 34601605. doi:10.1093/humrep/deab198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。